Selank regulatory status and Category 2 access in 2026
A plain-English look at where Selank stands with the FDA, and why the answer is "not yet."
TL;DR
- Selank is not FDA (Food and Drug Administration)-approved and sits on the FDA's Category 2 list as of July 2026.
- Category 2 (an FDA list of substances that may pose risks and are not available from 503A compounding pharmacies) means 503A pharmacies cannot legally compound it right now.
- A February 2026 HHS (Department of Health and Human Services) announcement proposed moving Selank toward Category 1. That change first requires a formal FDA Federal Register notice and PCAC (Pharmacy Compounding Advisory Committee) review.
Selank regulatory status: what it is
Selank is a synthetic peptide developed by Russian researchers, studied mainly for anxiety-related effects. It is not an FDA-approved medication. In the U.S. compounding system, it currently falls under Category 2 status. That status stops 503A (the section of federal law covering pharmacy compounding for individual patients) pharmacies from preparing it.
How it works
Think of Category 2 like a "hold" shelf at a pharmacy warehouse. The substance isn't destroyed or banned outright — it's set aside pending more safety review. Selank has been on that hold shelf since 2023, alongside other peptides the FDA flagged for closer evaluation.
Who asks about it
People researching nootropic or anti-anxiety peptides often find Selank mentioned alongside Semax. They want to know if it's legal, if a doctor can prescribe it, and whether the 2026 headlines about peptide reclassification apply to it specifically.
What the research says
Selank's evidence base is largely Russian, not Western. A 2008 study compared Selank to medazepam in 62 patients with generalized anxiety disorder and neurasthenia (PubMed, 2008). A 2014 study compared Selank to phenazepam in 60 patients with phobic-anxiety disorders. These are real human studies. But they are small, Russian-language, and fall short of the evidence the FDA requires for approval.
What to know before considering it
Selank cannot legally be compounded by a U.S. 503A pharmacy as of July 2026. The February 2026 HHS proposal named Selank among peptides considered for a return to Category 1. But nothing changes until the FDA publishes a Federal Register notice and PCAC completes its review. Timing beyond that is not yet set.
The Halftime POV
We do not prescribe Selank until it clears the FDA's process and a licensed clinician can dispense it legally. We would rather tell people "not yet, here's why" than promise access we cannot deliver.
Related reading:
- Why some peptides are still Category 2
- What Category 2 status means for TB-500, KPV, DSIP, and Epithalon in 2026
- The PCAC advisory committee: who decides which peptides are accessible
- Category 2 patient risk
FAQ
Q: Is Selank FDA-approved? A: No. Selank is not FDA (Food and Drug Administration)-approved for any use in the United States. It is currently classified as Category 2, meaning 503A compounding pharmacies cannot legally prepare it.
Q: What does Category 2 mean for Selank? A: Category 2 (an FDA list of substances that may pose risks and are not available from 503A compounding pharmacies) means Selank cannot be dispensed by 503A pharmacies right now. It does not mean Selank is illegal to research or banned outright.
Q: Can you get Selank from a compounding pharmacy in 2026? A: Not as of July 2026. A February 2026 HHS (Department of Health and Human Services) proposal suggested moving several peptides, including Selank, back to Category 1, but that change requires a formal FDA Federal Register notice and PCAC (Pharmacy Compounding Advisory Committee) review first.
Q: Is Selank's research based on human studies? A: Most Selank research comes from Russian institutions, including small human trials of around 60 to 120 patients for anxiety-related conditions. Western, FDA-standard clinical trials have not been completed.
Disclaimer
As of July 3, 2026, Selank is classified by the FDA as Category 2, which means it is not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning several peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
Frequently asked questions
Is Selank FDA-approved?
No. Selank is not FDA (Food and Drug Administration)-approved for any use in the United States. It is currently classified as Category 2, meaning 503A compounding pharmacies cannot legally prepare it.
What does Category 2 mean for Selank?
Category 2 (an FDA list of substances that may pose risks and are not available from 503A compounding pharmacies) means Selank cannot be dispensed by 503A pharmacies right now. It does not mean Selank is illegal to research or banned outright.
Can you get Selank from a compounding pharmacy in 2026?
Not as of July 2026. A February 2026 HHS (Department of Health and Human Services) proposal suggested moving several peptides, including Selank, back to Category 1, but that change requires a formal FDA Federal Register notice and PCAC (Pharmacy Compounding Advisory Committee) review first.
Is Selank's research based on human studies?
Most Selank research comes from Russian institutions, including small human trials of around 60 to 120 patients for anxiety-related conditions. Western, FDA-standard clinical trials have not been completed.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.